Mirum Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MIRM and other ETFs, options, and stocks.

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. 

CEO
Christopher Peetz
CEOChristopher Peetz
Employees
372
Employees372
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
2018
Founded2018
Employees
372
Employees372

MIRM Key Statistics

Market cap
7.44B
Market cap7.44B
Price-Earnings ratio
-8.98
Price-Earnings ratio-8.98
Dividend yield
Dividend yield
Average volume
1.07M
Average volume1.07M
High today
$126.89
High today$126.89
Low today
$118.61
Low today$118.61
Open price
$126.26
Open price$126.26
Volume
539.12K
Volume539.12K
52 Week high
$130.00
52 Week high$130.00
52 Week low
$50.25
52 Week low$50.25

Stock Snapshot

As of today, Mirum Pharmaceuticals(MIRM) shares are valued at $122.50. The company's market cap stands at 7.44B, with a P/E ratio of -8.98.

On 2026-07-11, Mirum Pharmaceuticals(MIRM) stock moved within a range of $118.61 to $126.89. With shares now at $122.50, the stock is trading +3.3% above its intraday low and -3.5% below the session's peak.

Trading activity shows a volume of 539.12K, compared to an average daily volume of 1.07M.

Over the past 52 weeks, Mirum Pharmaceuticals(MIRM) stock has traded between a high of $130.00 and a low of $50.25.

Over the past 52 weeks, Mirum Pharmaceuticals(MIRM) stock has traded between a high of $130.00 and a low of $50.25.

MIRM News

Investing.com 3d
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock - Investing.com

...

Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock - Investing.com
Simply Wall St 6d
FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals

Mirum Pharmaceuticals recently reported past positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva...

FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals

Analyst ratings

100%

of 14 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MIRM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.